Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783490 | 0.88 | PDE10A (0.33) | ALDH1A1 | |
| SCHEMBL4771762 | 0.86 | NOS2 (0.36) | — | |
| SCHEMBL4764107 | 0.86 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL5782870 | 0.84 | PDE6D (0.32) | ALDH1A1PDCD1CD274 | |
| SCHEMBL5780371 | 0.84 | — | — | |
| SCHEMBL4918500 | 0.83 | GRIN1 (0.32) | — | |
| SCHEMBL14166272 | 0.81 | — | — | |
| SCHEMBL4766360 | 0.80 | — | — | |
| SCHEMBL4767703 | 0.79 | PDE10A (0.32) | — | |
| SCHEMBL4770139 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560822-B1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORP (US) | 2006-08-09 | — | — | EP | claimed |
| US-6951864-B2 | 4-imidazol-1-ylmethyl-pyrimidine derivatives | NEUROGEN CORP. (US) | 2005-10-04 | — | — | US | claimed |
| EP-1560822-A1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS | Neurogen Corporation (US) | 2005-08-10 | — | — | EP | claimed |
| US-20040102457-A1 | 4-Imidazol-1-ylmethyl pyrimidine derivatives | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2004-05-27 | — | — | US | claimed |
| WO-2004041808-A1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES_AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORPORATION (GB) | 2004-05-21 | — | — | WO | claimed |
| US-6951864-B2 | 4-imidazol-1-ylmethyl-pyrimidine derivatives | NEUROGEN CORP. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040102457-A1 | 4-Imidazol-1-ylmethyl pyrimidine derivatives | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2004-05-27 | — | — | US | disclosed |
| WO-2004041808-A1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES_AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORPORATION (GB) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102457-A1 | 4-Imidazol-1-ylmethyl pyrimidine derivatives | GABRA1, GABRA4, GABRA3 | MAP4K4 3659/4885EGFR 1061/4885ALDH1A1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.